Literature DB >> 21752432

Lumican inhibits angiogenesis by interfering with α2β1 receptor activity and downregulating MMP-14 expression.

Jolanta Niewiarowska1, Stéphane Brézillon, Izabela Sacewicz-Hofman, Radoslaw Bednarek, François-Xavier Maquart, Mariusz Malinowski, Magdalena Wiktorska, Yanusz Wegrowski, Czeslaw S Cierniewski.   

Abstract

INTRODUCTION: Previous studies showed that lumican, a small leucine-rich proteoglycan that binds to α2 integrin I domain, is an efficient inhibitor of cell adhesion and migration. In this report, we tested its effect on angiogenesis in vitro and in vivo.
MATERIALS AND METHODS: Effect of lumican on angiogenesis was evaluated by in vitro capillary tube formation test performed between Fibrin II Gels or in Matrigel™ and in vivo by Matrigel(™) plug assay in BALB/c mice. Changes in matrix metalloproteinases expression caused by lumican were analyzed in endothelial cells by real-time PCR, Western immunoblotting and gelatin zymography.
RESULTS: In unchallenged endothelial cells, Matrigel™ induced robust capillary morphogenesis. In contrast, tube formation was dramatically reduced by lumican, and by siRNA to β1 integrin subunit mRNA but not by control siRNA. Similarly, lumican effectively inhibited neovascularization in vivo in assays using Matrigel™ plugs formed in BALB/c mice. Interestingly, lumican significantly reduced expression of matrix metalloproteinases, particularly MMP-14 that is known to activate other MMPs in close vicinity of endothelial cell membranes.
CONCLUSIONS: Our results provide strong evidence that lumican affects angiogenesis both by interfering with α2β1 receptor activity and downregulating proteolytic activity associated with surface membranes of endothelial cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752432     DOI: 10.1016/j.thromres.2011.06.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  38 in total

Review 1.  The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.

Authors:  A Hultgårdh-Nilsson; J Borén; S Chakravarti
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

Review 2.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

Review 3.  Matrix modeling and remodeling: A biological interplay regulating tissue homeostasis and diseases.

Authors:  Nikos K Karamanos; Achilleas D Theocharis; Thomas Neill; Renato V Iozzo
Journal:  Matrix Biol       Date:  2018-08-18       Impact factor: 11.583

4.  Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells.

Authors:  Zhen Yu; Lin Liu; Qiang Shu; Dong Li; Ran Wang
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

5.  Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer.

Authors:  Liang He; Dake Chu; Xia Li; Jianyong Zheng; Shanhong Liu; Jipeng Li; Qingchuan Zhao; Gang Ji
Journal:  Dig Dis Sci       Date:  2013-01-13       Impact factor: 3.199

Review 6.  The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly.

Authors:  Shoujun Chen; David E Birk
Journal:  FEBS J       Date:  2013-02-14       Impact factor: 5.542

7.  Fibromodulin promoted in vitro and in vivo angiogenesis.

Authors:  Jia Jian; Zhong Zheng; Kermit Zhang; Todd Matthew Rackohn; Chingyun Hsu; Andrew Levin; Dwarak Reddy Enjamuri; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Biochem Biophys Res Commun       Date:  2013-06-11       Impact factor: 3.575

8.  Lumican exhibits anti-angiogenic activity in a context specific manner.

Authors:  Bikram Sharma; Megan D Ramus; Christopher T Kirkwood; Emma E Sperry; Pao-Hsien Chu; Winston W Kao; Allan R Albig
Journal:  Cancer Microenviron       Date:  2013-06-18

9.  Lumican negatively controls the pathogenicity of murine encephalitic TH17 cells.

Authors:  Eliseo F Castillo; Handong Zheng; Christian Van Cabanlong; Fei Dong; Yan Luo; Yi Yang; Meilian Liu; Winston W-Y Kao; Xuexian O Yang
Journal:  Eur J Immunol       Date:  2016-10-24       Impact factor: 5.532

10.  Vixapatin (VP12), a c-type lectin-protein from Vipera xantina palestinae venom: characterization as a novel anti-angiogenic compound.

Authors:  Tatjana Momic; Gadi Cohen; Reuven Reich; Franziska T Arlinghaus; Johannes A Eble; Cezary Marcinkiewicz; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2012-10-18       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.